SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1 m advanced breast cancer during first-line endocrine-basedtherapy

Oncologist · Published 2026-07-23 · DOI 10.1093/oncolo/oyag278

Free full text

Authors (26)

Adam Brufsky, Yeon Hee Park, F.-C. Bidard, Erica L Mayer, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Hiroji Iwata, Peter A Fasching, Zbigniew Nowecki, Javier Pascual, Shin-Cheh Chen, Lionel Moreau, Manuel Ruiz-Borrego, Ayelet Shai, Nuri Karadurmus, Kyung Hae Jung, Yuichiro Kikawa, Richard D Baird, Ranya Habash, Rebecca Sugarman, Steven Fox, Manuel Selvi Miralles, Cynthia Huang Bartlett, Nicholas Turner

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Brufsky, A., Park, Y., Bidard, F., et al. (2026). SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1 m advanced breast cancer during first-line endocrine-basedtherapy. Oncologist. https://doi.org/10.1093/oncolo/oyag278

Related articles